Becton, Dickinson and Company (NYSE: BDX) Stock Competitors & Peer Comparison
See BDX's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BDX and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDX | $176.80 | -0.71% | 48.7B | 13.60 | $13.00 | +2.25% |
| ISRG | $391.95 | -2.32% | 138.5B | 40.74 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.25% |
| RMD | $218.89 | -1.02% | 31.8B | 20.33 | $10.77 | +1.12% |
| MDLN | $35.61 | +1.92% | 30.1B | 26.09 | $1.36 | N/A |
| WST | $364.98 | -0.01% | 25.7B | 42.94 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $87.85 | +0.09% | 15.2B | 12.37 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.25% |
| BAX | $23.49 | -0.63% | 12.1B | 11.29 | $2.08 | +0.17% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
BDX vs ISRG Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ISRG has a market cap of 138.5B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ISRG trades at $391.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ISRG's P/E ratio is 40.74. In terms of profitability, BDX's ROE is +0.04%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, BDX is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BDX vs BDXA Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BDX's ROE is +0.04%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BDXA's competition here
ResMed Inc. (NYSE: RMD)
BDX vs RMD Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, RMD has a market cap of 31.8B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while RMD trades at $218.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas RMD's P/E ratio is 20.33. In terms of profitability, BDX's ROE is +0.04%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BDX is less volatile compared to RMD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
BDX vs MDLN Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, MDLN has a market cap of 30.1B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while MDLN trades at $35.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas MDLN's P/E ratio is 26.09. In terms of profitability, BDX's ROE is +0.04%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BDX is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BDX vs WST Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while WST trades at $364.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas WST's P/E ratio is 42.94. In terms of profitability, BDX's ROE is +0.04%, compared to WST's ROE of +0.19%. Regarding short-term risk, BDX is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BDX.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BDX vs HOLX Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BDX's ROE is +0.04%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BDX is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BDX.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
BDX vs SOLV Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, SOLV has a market cap of 15.2B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while SOLV trades at $87.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas SOLV's P/E ratio is 12.37. In terms of profitability, BDX's ROE is +0.04%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, BDX is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for BDX.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BDX vs BDXB Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BDX's ROE is +0.04%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BDX vs BAX Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, BAX has a market cap of 12.1B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while BAX trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas BAX's P/E ratio is 11.29. In terms of profitability, BDX's ROE is +0.04%, compared to BAX's ROE of -0.17%. Regarding short-term risk, BDX is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BDX vs COO Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, COO has a market cap of 11.1B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while COO trades at $56.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas COO's P/E ratio is 12.48. In terms of profitability, BDX's ROE is +0.04%, compared to COO's ROE of +0.07%. Regarding short-term risk, BDX is less volatile compared to COO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
BDX vs AVTR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while AVTR trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas AVTR's P/E ratio is 18.04. In terms of profitability, BDX's ROE is +0.04%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BDX is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BDX vs RGEN Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, RGEN has a market cap of 10.3B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while RGEN trades at $181.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas RGEN's P/E ratio is 100.94. In terms of profitability, BDX's ROE is +0.04%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
BDX vs ATR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ATR trades at $119.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ATR's P/E ratio is 20.97. In terms of profitability, BDX's ROE is +0.04%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BDX is less volatile compared to ATR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BDX vs BLCO Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, BLCO has a market cap of 6.1B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while BLCO trades at $17.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas BLCO's P/E ratio is 26.31. In terms of profitability, BDX's ROE is +0.04%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BDX is less volatile compared to BLCO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BDX vs STVN Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, STVN has a market cap of 5.5B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while STVN trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas STVN's P/E ratio is 30.55. In terms of profitability, BDX's ROE is +0.04%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
BDX vs TFX Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while TFX trades at $124.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas TFX's P/E ratio is 14.19. In terms of profitability, BDX's ROE is +0.04%, compared to TFX's ROE of -0.32%. Regarding short-term risk, BDX is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BDX vs MMSI Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while MMSI trades at $85.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas MMSI's P/E ratio is 21.83. In terms of profitability, BDX's ROE is +0.04%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BDX is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BDX vs ICUI Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ICUI has a market cap of 4B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ICUI trades at $159.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ICUI's P/E ratio is 19.90. In terms of profitability, BDX's ROE is +0.04%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, BDX is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
BDX vs NVST Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, NVST has a market cap of 3.8B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while NVST trades at $23.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas NVST's P/E ratio is 15.96. In terms of profitability, BDX's ROE is +0.04%, compared to NVST's ROE of +0.03%. Regarding short-term risk, BDX is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BDX vs PLSE Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, PLSE has a market cap of 3.3B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while PLSE trades at $47.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas PLSE's P/E ratio is -40.59. In terms of profitability, BDX's ROE is +0.04%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, BDX is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BDX.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BDX vs ATRC Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ATRC has a market cap of 2.8B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ATRC trades at $55.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ATRC's P/E ratio is 1712.42. In terms of profitability, BDX's ROE is +0.04%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BDX is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BDX vs BLFS Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while BLFS trades at $37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas BLFS's P/E ratio is 36.21. In terms of profitability, BDX's ROE is +0.04%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, BDX is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BLFS's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BDX vs LMAT Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while LMAT trades at $78.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas LMAT's P/E ratio is 29.03. In terms of profitability, BDX's ROE is +0.04%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BDX is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
BDX vs AZTA Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, AZTA has a market cap of 1.8B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while AZTA trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas AZTA's P/E ratio is 92.26. In terms of profitability, BDX's ROE is +0.04%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BDX is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AZTA's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BDX vs XRAY Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while XRAY trades at $8.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas XRAY's P/E ratio is 6.06. In terms of profitability, BDX's ROE is +0.04%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, BDX is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check XRAY's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BDX vs KMTS Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while KMTS trades at $27.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas KMTS's P/E ratio is -10.35. In terms of profitability, BDX's ROE is +0.04%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, BDX is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BDX vs STAA Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while STAA trades at $22.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas STAA's P/E ratio is 39.42. In terms of profitability, BDX's ROE is +0.04%, compared to STAA's ROE of +0.01%. Regarding short-term risk, BDX is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
BDX vs ATRI Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BDX's ROE is +0.04%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BDX is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BDX vs ANGO Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ANGO has a market cap of 624.5M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ANGO trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ANGO's P/E ratio is -38.74. In terms of profitability, BDX's ROE is +0.04%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BDX is less volatile compared to ANGO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
BDX vs EMBC Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, EMBC has a market cap of 335.2M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while EMBC trades at $5.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas EMBC's P/E ratio is 2.17. In terms of profitability, BDX's ROE is +0.04%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, BDX is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BDX vs SMTI Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, SMTI has a market cap of 320.4M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while SMTI trades at $34.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas SMTI's P/E ratio is -580.83. In terms of profitability, BDX's ROE is +0.04%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BDX is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BDX.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BDX vs OSUR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, OSUR has a market cap of 273M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while OSUR trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas OSUR's P/E ratio is -5.75. In terms of profitability, BDX's ROE is +0.04%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BDX is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check OSUR's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BDX vs NNNN Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, NNNN has a market cap of 243.6M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while NNNN trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas NNNN's P/E ratio is 37.00. In terms of profitability, BDX's ROE is +0.04%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BDX is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NNNN's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BDX vs UTMD Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, UTMD has a market cap of 236M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while UTMD trades at $74.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas UTMD's P/E ratio is 21.93. In terms of profitability, BDX's ROE is +0.04%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BDX is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for BDX.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BDX vs PDEX Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, PDEX has a market cap of 204.6M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while PDEX trades at $64.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas PDEX's P/E ratio is 15.51. In terms of profitability, BDX's ROE is +0.04%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, BDX is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BDX.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BDX vs KRMD Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, KRMD has a market cap of 136M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while KRMD trades at $2.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas KRMD's P/E ratio is -74.00. In terms of profitability, BDX's ROE is +0.04%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BDX is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
BDX vs STXS Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, STXS has a market cap of 115.6M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while STXS trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas STXS's P/E ratio is -6.94. In terms of profitability, BDX's ROE is +0.04%, compared to STXS's ROE of -1.33%. Regarding short-term risk, BDX is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BDX vs AKYA Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BDX's ROE is +0.04%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BDX is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BDX.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
BDX vs DXR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, DXR has a market cap of 61.9M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while DXR trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas DXR's P/E ratio is 8.63. In terms of profitability, BDX's ROE is +0.04%, compared to DXR's ROE of +0.13%. Regarding short-term risk, BDX is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
BDX vs STSS Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas STSS's P/E ratio is -0.02. In terms of profitability, BDX's ROE is +0.04%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BDX is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BDX vs OMIC Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BDX's ROE is +0.04%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BDX is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BDX.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BDX vs IGAP Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BDX's ROE is +0.04%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, BDX is less volatile compared to IGAP. This indicates lower risk in terms of short-term price fluctuations for BDX.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BDX vs POCI Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, POCI has a market cap of 48.8M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while POCI trades at $4.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas POCI's P/E ratio is -9.70. In terms of profitability, BDX's ROE is +0.04%, compared to POCI's ROE of -0.24%. Regarding short-term risk, BDX is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check POCI's competition here
Nephros, Inc. (NASDAQ: NEPH)
BDX vs NEPH Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, NEPH has a market cap of 40.1M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while NEPH trades at $3.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas NEPH's P/E ratio is 61.50. In terms of profitability, BDX's ROE is +0.04%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, BDX is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NEPH's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BDX vs HBIO Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, HBIO has a market cap of 36.7M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while HBIO trades at $8.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas HBIO's P/E ratio is -22.58. In terms of profitability, BDX's ROE is +0.04%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BDX is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BDX vs MLSS Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, MLSS has a market cap of 33.5M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while MLSS trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas MLSS's P/E ratio is -7.57. In terms of profitability, BDX's ROE is +0.04%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BDX is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BDX.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BDX vs SDC Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas SDC's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.04%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BDX is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
BDX vs IVC Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas IVC's P/E ratio is -0.79. In terms of profitability, BDX's ROE is +0.04%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BDX is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BDX.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BDX vs RVP Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, RVP has a market cap of 21M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while RVP trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas RVP's P/E ratio is -5.83. In terms of profitability, BDX's ROE is +0.04%, compared to RVP's ROE of -0.05%. Regarding short-term risk, BDX is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
BDX vs BNGO Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, BNGO has a market cap of 17.2M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while BNGO trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas BNGO's P/E ratio is -0.50. In terms of profitability, BDX's ROE is +0.04%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, BDX is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for BDX.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BDX vs ZJYL Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ZJYL trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, BDX's ROE is +0.04%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BDX is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BDX vs RGNT Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, RGNT has a market cap of 12.7M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas RGNT's P/E ratio is -0.07. In terms of profitability, BDX's ROE is +0.04%, compared to RGNT's ROE of N/A. Regarding short-term risk, BDX is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BDX.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
BDX vs CUPR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, CUPR has a market cap of 6.5M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while CUPR trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas CUPR's P/E ratio is -1.75. In terms of profitability, BDX's ROE is +0.04%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, BDX is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
BDX vs FEMY Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, FEMY has a market cap of 6.3M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while FEMY trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas FEMY's P/E ratio is -0.46. In terms of profitability, BDX's ROE is +0.04%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, BDX is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
BDX vs LUCY Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, LUCY has a market cap of 5.6M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while LUCY trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas LUCY's P/E ratio is -0.69. In terms of profitability, BDX's ROE is +0.04%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BDX is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BDX vs NSTG Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BDX's ROE is +0.04%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BDX is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BDX vs POAI Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas POAI's P/E ratio is -0.38. In terms of profitability, BDX's ROE is +0.04%, compared to POAI's ROE of -21.19%. Regarding short-term risk, BDX is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BDX.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BDX vs MHUA Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BDX's ROE is +0.04%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BDX is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BDX.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BDX vs GMVD Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BDX's ROE is +0.04%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BDX vs GMVDW Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.04%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BDX is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BDX.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BDX vs AVGR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BDX's ROE is +0.04%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BDX is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BDX.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BDX vs NXGL Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while NXGL trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas NXGL's P/E ratio is -0.25. In terms of profitability, BDX's ROE is +0.04%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, BDX is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BDX.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BDX vs NXGLW Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, NXGLW has a market cap of 1.1M. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, BDX's ROE is +0.04%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, BDX is more volatile compared to NXGLW. This indicates higher risk in terms of short-term price fluctuations for BDX.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BDX vs LUCYW Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BDX's ROE is +0.04%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BDX is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BDX.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BDX vs ATRS Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BDX's ROE is +0.04%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BDX is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
BDX vs IVTY Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BDX's ROE is +0.04%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BDX is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IVTY's competition here
Apria, Inc. (NASDAQ: APR)
BDX vs APR Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, APR has a market cap of 0. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas APR's P/E ratio is 22.59. In terms of profitability, BDX's ROE is +0.04%, compared to APR's ROE of +9.81%. Regarding short-term risk, BDX is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BDX.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BDX vs HRC Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas HRC's P/E ratio is 41.92. In terms of profitability, BDX's ROE is +0.04%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BDX is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BDX.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
BDX vs ALOG Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BDX's ROE is +0.04%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BDX is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BDX.Check ALOG's competition here
IntriCon Corporation (NASDAQ: IIN)
BDX vs IIN Comparison October 2026
Becton, Dickinson and Company (NYSE: BDX) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDX stands at 48.7B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BDX is priced at $176.80 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDX currently has a P/E ratio of 13.60, whereas IIN's P/E ratio is 226.45. In terms of profitability, BDX's ROE is +0.04%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BDX is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BDX.Check IIN's competition here